|
THE
European Chamber of Commerce of the Philippines (ECCP)
said the passage of the cheap-medicines bill will be
useless if the government will not be able to improve
the accessibility of health care, particularly medical
professionals, and medicine to the public.
“Cheaper
medicine is not the solution. It’s the accessibility of
health care and medicine,” Henry Schumacher, ECCP
executive vice president, told reporters Thursday.
Schumacher said even if the bill is enacted, its
proponents will continue to be haunted by the fact that
a large portion of the population does not have access
to doctors who will give advice on the use of the
medicine.
“If you
don’t see the doctor, you will not see the pharmacist,”
Schumacher said.
Also,
Schumacher said the public needs to be equipped by the
government with the power to purchase the medicine they
need at the right dosage and price for the measure to be
useful.
He said
there should be more discussions on how the government
and the private sector can work together to make the
access to health care better.
Like in
the case of
Indonesia,
Schumacher said the government reimburses the expenses
for medicine and hospitalization of the poor sector. He
said a scheme should be devised to get the Philippine
Health Insurance Corp. involved in a reimbursement
system in the country.
Also,
Schumacher said the government and the pharmaceutical
firms can work together in coming up with two different
packaging for off-patent medicines, so one of them can
be sold by the state to the poor.
The
cheap-medicines bill, which aims to lower the cost of
drugs through the relaxing of patent laws and use of
parallel importation of cheaper versions of some drugs
from abroad, has been passed by the Senate and is now
just awaiting the approval of the House of
Representatives.
The ECCP
has in its fold at least 10 global pharmaceutical
companies, including Bayer, Glaxo and Hoechst.
Schumacher admitted that the pharmaceutical firms “have
never been a friend of the bill” because of its
provisions on the relaxation of patent rules. |